Literature DB >> 29079366

Quality of fracture reduction assessed by radiological parameters and its influence on functional results in patients with pilon fractures-A prospective multicentre study.

Christoph Sommer1, Sean E Nork2, Matthew Graves3, Michael Blauth4, Mark Rudin5, Karl Stoffel6.   

Abstract

INTRODUCTION: The management of pilon fractures remains a challenging issue. Due to the complexity of factors that influence the outcome, it has been questioned if anatomical reductions of articular fracture are relevant. The lack of a commonly accepted assessment of quality of fracture reduction compounded the uncertainty of the importance of anatomical reduction in pilon fracture. The current study aimed to define parameters that can better assess the reduction quality and to investigate the influence of reduction quality on functional outcomes.
METHODS: Patients with unilateral pilon fracture of the AO/OTA type 43-B or 43-C were consecutively recruited to the study and followed up for 2 years after surgery. Postoperative radiographs of the injured and the contralateral joints were evaluated and 13 radiological parameters measured by 2 independent surgeons. The reliability of the measurements for each parameter was assessed by the Intraclass Correlation Coefficient (ICC), and 4 parameters with the highest ICC scores were deemed most reliable and were selected for further analyses. Functional outcome was assessed by the Foot and Ankle Ability Measure (FAAM) for daily living and sports activities. The 4 most reliable radiologic parameters, together with 3 possible baseline confounders (age, AO/OTA fracture type, and open versus closed injury), were analysed using both univariable and multivariable analysis for their association with the FAAM scores. Secondary outcome measures including pain, ankle range of motion (ROM), quality of life (QoL), and adverse events were also reported.
RESULTS: The length of lateral malleolus (LLM), anterior distal tibia angle, anterior talar shift, and length of medial malleolus scored highest on reliability in ICC assessment (ICC=0.76, 0.72, 0.58, and 0.45, respectively). Only LLM exhibited statistical significant association with the 2-year FAAM results. At the 2-year follow-up, the injured joints on average achieved a ROM of 70.7% (95% CI=63.9-77.6) when compared to the contralateral joints, and patients did not regain the pre-injury QoL overall.
CONCLUSION: The multivariable analysis showed that LLM (independent of age, AO/OTA fracture type, and open/closed injury) was a reliable indicator of reduction quality and a prognostic factor for patient outcome in pilon fracture surgery.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  ORIF; Outcome; Pilon fracture; Quality of reduction

Mesh:

Year:  2017        PMID: 29079366     DOI: 10.1016/j.injury.2017.10.031

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  4 in total

1.  Treatment of unstable extra-articular distal radius fractures using locked volar plating and percutaneous pinning without external fixation.

Authors:  Saeid Sadeghi Joni; Pedram Yavari; Peyman Tavakoli; Pedram Tavoosi; Ghasem Mohammadsharifi
Journal:  Int J Burns Trauma       Date:  2020-08-15

Review 2.  Evolution in Management of Tibial Pilon Fractures.

Authors:  Jessica Bear; Natalie Rollick; David Helfet
Journal:  Curr Rev Musculoskelet Med       Date:  2018-12

3.  Impaction fractures of the anterior tibial plafond: Outcomes after fractures around the ankle: Is the anterior impaction plafond fracture a problem?

Authors:  Moaz B Y Chohan; Christopher Del Balso; Michael Ching; Emil Schemitsch; Abdel Rahman Lawendy; David W Sanders
Journal:  OTA Int       Date:  2020-05-21

4.  Tips and Tricks in surgical reduction of the posterior column of AO/OTA C3 pilon fractures.

Authors:  Moran Huang; Qiuke Wang; Junjie Guan; Kexin Liu; Yunfeng Chen; Lei Wang
Journal:  BMC Musculoskelet Disord       Date:  2022-01-03       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.